Monday, November 3, 2025
AAVantgarde to Advance Clinical Programs in Stargardt Disease, Usher 1B Syndrome
Proceeds from Series B financing will support the completion of AAVantgarde’s AAVB-039 CELESTE study, the STELLA natural history study, and the AAVB-081 LUCE phase 1/2 clinical trial.
  
            

